Teva expected to pay big bucks for decision to use oversized vials

Teva Pharamaceuticals ($TEVA) is discovering size matters. The Israeli generics giant reportedly is setting aside $285 million to settle lawsuits alleging the jumbo-sized vials it used for its anesthetic propofol encouraged re-use and led to colonoscopy patients developing hepatitis C. The company no longer makes the drug. The money will settle about 120 lawsuits, mostly from patients of a Nevada colonoscopy center. It will also settle a case in which it faced a $500 million jury award. Story


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.